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With DiabetesClaudia S. Cabrera1,2, Alison S. Lee3, Marita Olsson4,5, Volker Schnecke6, Klara Westman7,
Marcus Lind7,8, Peter J. Greasley4,9 and Stanko Skrtic10,11
1Real World Science and Digital, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden; 2Department of Medical
Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; 3Commonwealth Informatics, Inc., Waltham, Mas-
sachusetts, USA; 4AstraZeneca, Gothenburg, Sweden; 5Department of Mathematical Sciences, Chalmers University of Tech-
nology, Gothenburg, Sweden; 6Novo Nordisk, Søborg, Denmark; 7Institute of Medicine, Sahlgrenska Academy, University of
Gothenburg, Gothenburg, Sweden; 8Department of Medicine, NU-Hospital Group, Uddevalla Hospital, Uddevalla, Sweden;
9Early Clinical Development, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM) Bio-
Pharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; 10Innovation Strategies and External Liaison, Pharmaceutical
Technology and Development, AstraZeneca Gothenburg, Gothenburg, Sweden; and 11Institute of Medicine, Sahlgrenska
Academy, University of Gothenburg, Gothenburg, SwedenIntroduction: It remains unclear whether an increased progression rate of chronic kidney disease (CKD)
adds predictive information regarding cardiovascular disease (CVD) risk. The aim of this study was to
evaluate the association between CKD progression, based on estimated glomerular filtration rate (eGFR)
slope estimates and the risk for CVD.
Methods: We compared the updated eGFR slope calculated over multiple overlapping 2-year periods and
the updated mean eGFR. Incident CKD subjects were selected from a prevalent population with diabetes
(T2DM). Subjects from the UK Clinical Practice Research Data Link GOLD (CPRD) were followed from CKD
diagnosis (n ¼ 30,222) until heart failure (HF), myocardial infarction (MI), ischemic stroke (IS), or a com-
posite end point including all 3 event types (MACE plus), mortality, database dropout, or end of study
follow-up.
Results: Both the updated eGFR slope and updated mean eGFR were associated with MACE plus and HF.
Updated eGFR slope decline of > –3 ml/min/1.73 m2 increased the risk for MACE plus (adjusted hazard
ratio [HR] ¼ 1.45; 95% confidence interval [CI], 1.26–1.67), HF (HR ¼ 1.50; 95% CI, 1.27–1.76), and MI (HR ¼
1.39; 95% CI, 1.01–1.91).
Conclusions: This study strongly supports current evidence that CKD is an independent risk factor for CVD.
From a clinical perspective, both rate of progression and cumulative status of CKD describe distinct as-
pects of the cardiorenal risk among persons with diabetes. This evidence is essential to enable more timely
and improved use of treatments in this population.
Kidney Int Rep (2020) 5, 1651–1660; https://doi.org/10.1016/j.ekir.2020.07.029
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hronic kidney disease (CKD) is an increasing global
health problem.1 In 2016, the prevalence of
chronic kidney disease was estimated to be 13.4%
globally, increasing up to 35% in the elderly popula-
tion.2 Data from Health Surveys from Englandspondence: Claudia Cabrera, AstraZeneca BioPharmaceuticals
al, Pepparedsleden, 1SE-431 83 Gothenburg, Sweden. E-mail:
a.s.cabrera@astrazeneca.com
ved 12 December 2019; revised 29 June 2020; accepted 28
020; published online 7 August 2020
International Reports (2020) 5, 1651–1660estimated a population prevalence of CKD in the United
Kingdom (UK) of 6% in men and 7% in women in
2010.3 Treatment options to slow CKD progression and
address associated risks are limited, and in 2010, CKD
ranked as the 18th most common cause of mortality.4
The National Health and Nutrition Examination Sur-
vey study from 2016 estimated that 6.9% of the US
population had CKD stages 3 and 4 (glomerular filtra-
tion rate [GFR], 15–59 ml/min/1.73 m2) in 2011.5 In
Western countries, type 2 diabetes mellitus (T2DM) is
attributed as the leading cause of CKD, accounting for1651
CLINICAL RESEARCH CS Cabrera et al.: Diabetic Nephropathyover 40% of the disease population.6–9 The increase in
patients with T2DM and associated microvascular dis-
ease is by inference driving the prevalence of diabetes-
associated nephropathy.10–12
Morbidity and mortality in patients with diabetic
kidney disease predominantly result from cardiovas-
cular disease (CVD).13,14 Several studies have demon-
strated a strong association between CKD and CVD; this
is further pronounced in persons with T2DM.15,16 Less
is known about the frequency and characteristics of
CKD progression in relation to CVD outcomes and
background factors such as hypertensive treatment and
concomitant disease.17 Moreover, reported increased
morbidity in patients with CKD may be limited by a
priori assumptions that reductions in estimated GFR
(eGFR) are stable over time.18 Matsushita et al.19 in 2009
was first to note that an annual decline in GFR using
the Modification of Diet in Renal Disease study equa-
tion, measured at 2 points in time, was associated with
coronary heart disease. A more recent meta-analysis by
Greene et al.20 assessed eGFR slope as a surrogate end
point for renal disease and found it to be correlated
with multiple risk factors, treatment, and study design,
but critical to CKD patient segmentation.
Today, it remains unclear whether the increased
progression rate of CKD adds information regarding
CVD risk outcomes; consequently, it remains difficult
to time cardiovascular medicine prevention accurately
in this patient population. Therefore, the main
objective in this study was to evaluate the association
between the rate of CKD progression, based on the
eGFR and incidence of CVD types: heart failure (HF),
myocardial infarction (MI), ischemic stroke (IS), and
MACE plus (a composite variable including all CVD
events) in a large contemporary population of CKD
patients with T2DM newly provided a diagnosis in
the UK.METHODS
Data were obtained from the Clinical Practice Research
Data Link (CPRD), in which primary health care prac-
titioners in the UK record patient information captured
through Electronic Health Record information tech-
nology systems, and which are updated at regular in-
tervals. The CPRD covers approximately 8% of the UK
population and is representative of the general popu-
lation in terms of age, sex, and ethnicity.21 The CPRD
provides anonymous health care data that include de-
mographic, laboratory, prescribed drug, and diagnosis
information.22 Ethical approval was granted by the
CPRD scientific committee and the National Informa-
tion Governance Board of Ethics and Confidentiality
Committee (approved by the Independent Scientific1652Advisory Committee for Medicines and Healthcare
products Regulatory Agency database research ID no.
ISAC 11_26).
We identified 30,222 newly diagnosed CKD subjects
from a prevalent population of T2DM, described in
Figure 1. The original T2DM population included men
and women with a medical code for diabetes mellitus or
antidiabetic treatment codes from 1 January 1995 to 31
December 2015. Patients with a record of type 1 dia-
betes or malignancy were excluded. The T2DM popu-
lation was then further restricted to those for whom a
medical diagnosis based on Read codes for CKD was
present from 1 January 2005 to 31 December 2015 and
for whom the CKD selection date (index date) occurred
after T2DM diagnosis. Patients were also required to
have had at least 12 months of data before the CKD
index date. All CKD patients with a history of CVD (HF,
MI, IS, or MACE plus) during the year before CKD
index or the 2 years after CKD index (baseline period)
were excluded to ensure incident cases were captured
during the follow-up period. Baseline CKD status was
determined by taking the last eGFR in the year before
CKD index or the first eGFR after the CKD index date to
ensure the full CKD population was captured.
All covariates were estimated and defined during an
initial 2-year baseline period. This 2-year period
allowed patients to stabilize in treatment for both CVD
and T2DM after the CKD diagnosis and to estimate
background characteristics, including the baseline
slope. Patients with >2 serum creatinine values in this
2-year baseline period were excluded from the study.
The following baseline covariates were derived by
averaging values during the initial 2-year period: body
mass index (kg/m2), systolic and diastolic blood pres-
sure (mm Hg), triglycerides (mmol/l), low-density li-
poprotein (mmol/l), potassium (mmol/l), and
hyperkalemia (mean potassium > 5.5 mmol/l). Hyper-
tensive medication for CVD subjects included baseline
renin–angiotensin–aldosterone system inhibitors
(RAASis) angiotensin II receptor blockers, and
angiotensin-converting enzyme inhibitors and miner-
alocorticoid receptor antagonist use with at least 2
prescriptions with British National Formulary codes
within the 2-year baseline period. Baseline smoking
status was defined as the worst smoking category
(nonsmoker, ex-smoker, or current smoker) recorded
during the baseline period, and age (range, 19–103
years) was recorded on the subject’s CKD index date.
Where missing values occurred, a category was created
to describe missingness per variable.
The Chronic Kidney Disease Epi Equation23 was used
to calculate eGFR; other formulas were previously
assessed in CPRD by that group (Cabrera, C, Asiimwe
A, Lee A. Estimating chronic kidney disease in a UKKidney International Reports (2020) 5, 1651–1660
CS Cabrera et al.: Diabetic Nephropathy CLINICAL RESEARCHpopulation with type II diabetes mellitus. [abstract].
Pharmacoepidemiol Drug Saf. 2012;21:S273). When
calculating eGFR, any serum creatinine values that
were >35 mmol/l or >1500 mmol/l were excluded from
further eGFR calculations.24 Three approaches for
computing eGFR change over time were tested to
identify which was the most appropriate time-varying
method to estimate CVD events in a statistical model.
They included a baseline slope of eGFR (ml/min/1.73
m2/2-year period), the updated eGFR slope calculated
over multiple overlapping 2-year periods, and the
updated mean eGFR per 2-year slope period, all based
on the Chronic Kidney Disease Epi Equation formula.23
The baseline slope and updated mean per slope period
(in which mean values were included in categories $60
versus$30 to 60, and <30 ml/min/1.73 m2), along with
the updated eGFR slope categories (reference: $3; $0
to <3, <0 to –3, and < –3 ml/min/1.73 m2) were the
main variables of interest. The categorical updated
eGFR slope was analyzed in relation to CVD morbidity
for persons with T2DM in whom the most positive
slope inclination was the reference category. The
reference category $3 was chosen because it is the
most beneficial category (least disease progression) for aFigure 1. Flowchart describing the final cohort of adults with type 2 diab
ratio; IS, ischemic stroke; MI, myocardial infarction.
Kidney International Reports (2020) 5, 1651–1660patient, which facilitates trend assessments in hazard
ratios (HRs) across categories ordered according to
severity. A linear regression equation was used to
determine the rate of progression (slope) over the
baseline 2-year period; then, it was applied for subse-
quent overlapping 2-year periods.
The main time-dependent variable of interest was
based on multiple updated slopes which were calcu-
lated throughout the follow-up from overlapping 2-
year periods.
The eGFR slopes were calculated within each 2-year
period beginning with the first eGFR measure recorded
at least 6 months after the start of the previous slope.
The first postbaseline slope for each patient began on
day 0 (first day of the at-risk period). Standard practice
in the UK and for CPRD since 2004, when the Quality
and Outcomes Framework was initiated, has been to
measure eGFR approximately twice a year for each
patient.25,26 This allows the slope estimates to be based
on multiple measures over time with at least 2 eGFR
estimates for each 2-year period per individual, as
further described in Table 1. Chronic kidney disease
progression was estimated over time with an average of
5 overlapping slopes per subject.etes mellitus (T2DM) and chronic kidney disease (CKD). HF, hazard
1653





(y) ¼ a þ bx
Slope (b) ¼ (NSXY – [SX] [SY]) / (NSX2 – [SX]2)
Intercept (a) ¼ (SY – b[SX]) / N
N ¼ number of serum creatinine tests in a 2-yr period
X ¼ years from CKD index (date of the serum creatinine test in years from CKD index date)
Y ¼ eGFR value calculated from serum creatinine values (Chronic Kidney Disease Epi Equation formula)
Baseline slope Calculated from all eGFR values reported for the subject over the initial 2-yr baseline period using standard regression equation for slope
Baseline 2-yr period All covariates were estimated and defined during an initial 2-yr baseline period starting from CKD index date
Follow-up period Starts directly after the 2-yr baseline period. The end of the follow-up is defined as the first occurrence of a CVD event, subject lost to follow-up, or 31 December
2015, whichever comes first
Overlapping time windows For each subject, the follow-up period is covered by overlapping time windows. The first time window covers the first 2 yr of the follow-up period. The second
time window starts at the first eGFR value registered at least 6 mo after the start date of follow-up and stretches over the following 2 yr or to the end of follow-up.
The next window starts at least 6 mo after the start of the previous time window, and so on until the whole follow-up is covered
Updated slope The first slope is based on all eGFR values in the subject’s first time window (baseline 2-yr period), the second slope is based on all eGFR values in the second
time window, and so on. In general, each subject will have multiple overlapping slopes, in which each slope represents the direction of change (or rate of
progression) in eGFR during the previous 2 yr
Updated mean The first mean is the mean of all eGFR values in the first time window, the second mean is based on all eGFR values in the second time window, and so forth. For
each subject at each time point, in general, the updated mean eGFR represents the average level in eGFR over the last 2 yr
CKD, chronic kidney disease.
CLINICAL RESEARCH CS Cabrera et al.: Diabetic NephropathyFor each CKD variable we created statistical models
to assess CVD morbidity end points. Associations be-
tween CKD variables and CVD outcomes were estimated
using Cox proportional hazards regression models.
Each CKD progression estimate was analyzed in a model
adjusted for confounders potentially relevant to CVD.
Follow-up began directly after the initial 2-year baseline
period. The time scale in the statistical model is based in
years to estimate the annual decline in eGFR. Patients
with no serum creatinine laboratory values after the in-
dex date or with a gap of more than 2 years between
serum creatinine measures were excluded. We also con-
ducted sensitivity analyses restricting slope inclinations
(< –20 and >20) and found the model to be stable, (data
not shown). In addition, baseline characteristics of the
original prevalent T2DM cohort from 2005 to 2015 were
also assessed by CVD outcomes. Supplemental Table S1
compares results obtained from our main analysis that
assessed T2DM patients with CKD. Results from the
proportional hazards models are presented as (relative
risks [HRs]) and 95% confidence intervals (CIs).
Morbidity end points for the HRs were identified
with READ codes and included HF, MI, IS, and a
composite variable MACE plus, which included all
CVD morbidity outcomes. The follow-up time used to
estimate the time to an event was defined as the
remaining study period after the initial 2-year baseline
period. SAS software (version 9, SAS Institute, Cary,
NC) was used for the analyses.RESULTS
The baseline characteristics in Table 2 illustrate a study
population of 30,222 CKD subjects newly provided1654with a diagnosis from a cohort of prevalent T2DM
subjects, stratified according to the eGFR slope cate-
gories per 2-year period ($3, $0 to <3, <0 to –3,
and # –3 ml/min/1.73 m2) and cumulative incidence of
morbidity end points (MACE plus, n ¼ 2304; HF, n ¼
1691; MI, n ¼ 459; and IS, n ¼ 302).
Median follow-up was 4.3 years (interquartile range,
2.4–6.4 years) during which a mean of 11 eGFR values/
patient were captured. Women comprised 54% of the
cohort. Mean age was 71 years at CKD diagnosis, mean
systolic blood pressure was 138 mm Hg, and 82% of
the population was categorized as overweight or obese
(body mass index, $25 kg/m2). Baseline medication
demonstrated that 82% were receiving angiotensin-
converting enzyme inhibitor or angiotensin II recep-
tor blocker medication, 4% were receiving a mineral-
ocorticoid receptor antagonist treatment, and
approximately 2% indicated a possible hyperkalemic
state during the baseline period. Median duration with
T2DM was 5 years (interquartile range, 2.3–8.5 years),
and 53% were smokers or ex-smokers. The cumulative
incidence rate of CVD morbidity was MACE plus 7.6%,
HF 5.6%, MI 1.5%, and IS 1%. This is illustrated in
Figure 2, in which the updated mean eGFRs per slope
period are plotted over the follow-up time and by
incident CVD outcomes. Box plots indicate mean eGFR
and range for all individuals during the 2-year baseline
period, in which the predominant CVD diagnosis in
this CKD population was HF.
Multivariable associations between covariables
included in the models and CKD indicators are
demonstrated in Table 3 for eGFR slope categories. Risk
for CVD outcomes increased with age across end points
by approximately 4%/y (MACE plus HR ¼ 1.41; 95%Kidney International Reports (2020) 5, 1651–1660
Table 2. Baseline characteristics in UK individuals with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), by renal disease
progression and cardiovascular disease outcomes
Baseline variables














< --3 Slope --3 to <0 Slope 0--3 Slope ‡3
N (%)a 30,222 8011 (27) 7399 (24) 6731 (22) 8081 (27) 1691 (5.6) 459 (1.5) 302 (1) 2304 (7.6)
Age, yr Mean (SD) 71 (11) 71 (11) 72 (10) 71 (10) 69 (11) 74 (9) 73 (10) 74 (10) 74 (9)
Male gender n (%) 13,942 (46) 3858 (48) 3522 (48) 3037 (45) 3525 (44) 882 (52) 273 (59) 140 (46) 1213 (53)
eGFR,b ml/min/1.73
m2
Mean (SD) 52 (16) 55 (16) 50 (17) 50 (16) 52 (15) 47 (13) 49 (16) 47 (13) 47 (14)
eGFR <60, ml/min/
1.73 m2
n (%) 23,782 (79) 5832 (73) 6028 (82) 5512 (82) 6410 (79) 1502 (89) 382 (83) 260 (86) 2015 (88)
Smoker (yes)c n (%) 3387 (11) 981 (12) 740 (10) 696 (10) 970 (12) 189 (11) 64 (14) 35 (12) 269 (12)
Systolic blood
pressure, mm Hg
Mean (SD) 138 (13) 139 (14) 138 (13) 138 (13) 137 (13) 139 (15) 140 (14) 139 (14) 139 (15)
Diastolic blood
pressure, mm Hg
Mean (SD) 75 (7) 75 (8) 74 (7) 75 (7) 75 (7) 73 (8) 74 (8) 74 (7) 74 (8)
Body mass index, kg/
m2
Mean (SD) 30.6 (6) 30.8 (6) 30.5 (6) 30.4 (6) 30.7 (6) 31 (6) 30 (6) 30.1 (5) 30.7 (6)
Low-density
lipoprotein, mmol/l
Mean (SD) 84 (29) 83 (30) 83(29) 84 (29) 85 (30) 82 (29) 86 (29) 83 (29) 83 (29)
Triglycerides, mmol/l Mean (SD) 162 (83) 165(85) 162 (83) 159 (81) 161 (83) 166 (86) 171 (92) 168 (95) 167 (88)
Hyperkalemia >5.5
mmol/l (yes)









n (%) 1297 (4) 482 (6) 266 (4) 251 (4) 298 (4) 172 (10) 29 (6) 14 (5) 204 (9)
T2DM duration $5 yr n (%) 15,267 (51) 4342 (54) 3824 (52) 3363 (50) 3738 (46) 999 (59) 258 (56) 168 (56) 1333 (58)
eGFR, estimated glomerular filtration rate.
aCumulative incidence rates for cardiovascular disease outcomes.
beGFR was estimated using the Chronic Kidney Disease Epi Equation.
cApproximately 40% were classified as ex-smokers across all categories.
dRenin–angiotensin–aldosterone system inhibitor medication includes angiotensin II receptor blockers and angiotensin-converting enzyme inhibitor medication (yes).
CS Cabrera et al.: Diabetic Nephropathy CLINICAL RESEARCHCI, 1.27–1.56) and men were at greater risk compared
with women. Other factors that had significant associa-
tions beyond CKD progression to CVD includedFigure 2. Updated mean estimated glomerular filtration rate (eGFR) in ch
illustrated over time and by incident cardiovascular disease outcomes.
Kidney International Reports (2020) 5, 1651–1660angiotensin-converting enzyme inhibitor or angiotensin
II receptor blocker (HR ¼ 1.29; 95% CI, 1.08–1.53) and
mineralocorticoid receptor antagonist (HR ¼ 2.96; 95%,ronic kidney disease (CKD) subjects with type 2 diabetes mellitus
1655
Table 3. Multivariable association between categorical eGFR updated slope measure and cardiovascular disease outcomes in 30,222 adults
with type 2 diabetes mellitus and CKDa
Model covariates Heart failure (n [ 1185) Myocardial infarction (n [ 311) Ischemic stroke (n [ 195) MACE plus (n [ 1588)
Age at baseline, yr 1.05 (1.04--1.05) 1.02 (1.01--1.04) 1.05 (1.04--1.07) 1.04 (1.04--1.05)
Male gender 1.34 (1.18--1.51) 1.85 (1.46--2.35) 1.19 (0.88–1.60) 1.41 (1.27--1.56)
CKD updated slope categories¤
Updated eGFR slope $3 Reference group Reference group Reference group Reference group
Updated eGFR slope 0–3 1.02 (0.85–1.23) 1.10 (0.78–1.57) 1.19 (0.76–1.85) 1.06 (0.90–1.24)
Updated eGFR slope –3 to <0 1.23 (1.03--1.47) 1.16 (0.83–1.63) 1.32 (0.86–2.01) 1.22 (1.05--1.42)
Updated eGFR slope eGFR < –3 1.50 (1.27--1.76) 1.39 (1.01--1.91) 1.33 (0.88–2.01) 1.45 (1.26--1.67)
Never-smoker Reference group Reference group Reference group Reference group
Ex-smoker 1.14 (1.01--1.30) 1.03 (0.80–1.31) 0.89 (0.65–1.22) 1.09 (0.98–1.21)
Current smoker 1.35 (1.11--1.64) 1.28 (0.89–1.83) 1.43 (0.91–2.23) 1.33 (1.13--1.57)
Systolic blood pressure, mm Hg 1.01 (1.00–1.01) 1.02 (1.01–1.03) 1.00 (0.99–1.01) 1.01 (1.00–1.01)
Diastolic blood pressure, mm Hg 0.98 (0.97–0.99) 0.98 (0.96–1.00) 1.01 (0.98–1.03) 0.99 (0.98–0.99)
Body mass index $25 kg/m2 1.23 (1.04--1.45) 0.81 (0.61–1.08) 1.10 (0.75–1.62) 1.13 (0.98–1.30)
Low-density lipoprotein, mmol/lb 1.00 (1.00–1.00) 1.00 (1.00–1.01) 1.00 (1.00–1.01) 1.00 (1.00–1.00)
Triglycerides, mmol/lc 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
Hyperkalemia >5.5 mmol/l 1.32 (0.97–1.81) 1.29 (0.71–2.37) 1.29 (0.57–2.92) 1.32 (1.01--1.74)
Renin–angiotensin–aldosterone system inhibitors medication 1.29 (1.08--1.53) 0.94 (0.69–1.28) 0.93 (0.64–1.35) 1.17 (1.01--1.35)
Mineralocorticoid receptor antagonist treatment 2.96 (2.44--3.59) 1.29 (0.75–2.21) 1.00 (0.47–2.14) 2.50 (2.09--2.99)
Diabetes duration $5 yr 1.36 (1.21--1.53) 1.34 (1.07--1.68) 1.26 (0.94–1.67) 1.35 (1.22--1.49)
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
aData are shown as hazard ratio (95% confidence interval). Estimated glomerular filtration rate slopes are based on the Chronic Kidney Disease Epi Equation by Levey et al.23 British
National Formulary coding was used for mineralocorticoid receptor antagonist and renin–angiotensin–aldosterone system inhibitor medication angiotensin-converting enzyme inhibitors
or angiotensin II receptor blockers. Exclusions were all prevalent cardiovascular disease events before follow-up.
bMissing for low-density lipoprotein n ¼ 7438 (24.6%);
cMissing for triglycerides n ¼ 4668 (15.5%). ¤
Bold text indicates statistically significant results.
CLINICAL RESEARCH CS Cabrera et al.: Diabetic NephropathyCI 2.44–3.59) treatment among T2DM patients with CKD
in relation to HF. Having T2DM for over 5 years at the
time of CKD diagnosis also significantly increased CVD
outcomes, except for IS, by approximately 35%. Smoking
(HR ¼ 1.35; 95% CI, 1.11–1.64) and being overweight
(HR ¼ 1.23; 95% CI, 1.04–1.45) were both significantly
associated with HF events. Similar associations were
noted for all adjusted multivariable model results. Spe-
cific outcomes for each eGFR indicator type are shown in
Supplementary Table S2.
Regardless of T2DM status and generally accepted risk
factors for CVD, renal function defined by eGFR remained
an independent risk factor for heart disease. The updated
eGFR slope ($3 ml/min/1.73 m2 per 2-year period) was the
reference category indicating no renal disease progression,
which was compared with successively greater renal
deterioration across the other slope categories. The fastest
progressors of CKD, as assessed by their updated eGFR
slopes over time of # –3, were significantly associated
with HF (HR ¼ 1.50; 95% CI, 1.27–1.76), MI (HR ¼ 1.39;
95% CI, 1.01–1.91), and MACE plus (HR ¼ 1.45; 95% CI,
1.26–1.67). All other eGFR measures (eGFR updated mean,
slopes as a continuous estimate, updated slope, and both
the updated mean and slope entered in the same model)
were included in similar models that demonstrated asso-
ciations equivalent to those of CVD outcomes. Adjusted
risk estimates are shown in Figure 3.
Figure 3 presents HR estimates, including the main
eGFR measures assessing current status and progression1656of CKD both alone as the main variable of interest and
together in the same model. When assessed alone, in
the model, the updated mean eGFR showed a gradient
effect when the 2 more severe categories of CKD were
compared with the reference category of $60 across all
CVD outcomes. This association was most strongly
noted in IS (HR ¼ 2.72; 95% CI, 1.59–4.68), closely
followed by HF (HR ¼ 2.34; 95% CI, 1.86–2.94), MACE
plus (HR ¼ 2.33; 95% CI, 1.92–2.84), and MI (HR ¼
2.25; 95% CI, 1.47–3.45).
In the model in which the updated mean eGFR per 2-
year slope intervals and updated eGFR slope were
assessed simultaneously, the most current estimate of
eGFR as measured by the updated mean demonstrated a
stronger although slightly attenuated correlation
compared with CVD outcomes over time, as illustrated
by the MACE plus HRs for updated mean eGFR $ 30–
60 ml/min/1.73 m2 (HR ¼ 1.59; 95% CI, 1.37–1.86) and
updated mean eGFR <30 ml/min/1.73 m2 (HR ¼ 2.24;
95% CI, 1.84–2.74). The updated eGFR slope measures
in the most rapidly progressing category, defined by a
slope of < –3 ml/min/1.73 m2, were strongly associated
with HF (HR ¼ 1.38; 95% CI, 1.17–1.63) and MACE
plus (HR ¼ 1.34; 95% CI, 1.16–1.54) and less so with
other CVD outcomes compared with the reference
category (in which no progression in renal disease is
assumed). Other categories of the updated eGFR slope
were no longer statistically associated with CVD when
the updated mean measure was included as a covariableKidney International Reports (2020) 5, 1651–1660
Figure 3. Proportional hazards regression models in 30,222 patients with associated diabetic nephropathy estimating time to cardiovascular
disease outcomes by updated mean and updated estimated glomerular filtration (eGFR) slope. Hazard ratios for chronic kidney disease var-
iables and 95% confidence intervals are based on the linear effect model per mean or slope and categorized eGFR slope variables. Fully
adjusted models include the baseline variables of age, sex, body mass index, systolic blood pressure, disatolic blood pressure, low-density
lipoprotein, triglycerides, type 2 diabetes mellitus dutation, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers,
mineralocorticoid receptor antagonist treatment, and hyperkalemia. *eGFR updated mean category$60 ml and updated slope$3 are reference
categories. **Updated mean and updated slope were assessed in the same model; interaction effects were nonsignificant for all events
analyzed (results not shown).
CS Cabrera et al.: Diabetic Nephropathy CLINICAL RESEARCHin the model. Baseline eGFR slopes were also assessed
and results were similar to those noted for the eGFR
updated slope models. For instance, when baseline
slope inclination category < –3 was compared with the
referent level$3 in a fully adjusted model, the following
resultswere noted:MACEplus (HR¼ 1.24; 95%CI, 1.08–
1.43) and HF (HR ¼ 1.20; 95% CI, 1.02–1.41).
DISCUSSION
The association between renal disease progression and
CVD risk was assessed among patients with T2DM and
CKD in a UK primary health care setting. We found
that progression of CKD appears to be associated withKidney International Reports (2020) 5, 1651–1660CVD risk, in which a monotonic increased risk of car-
diovascular events was noted among those with the
fastest rate of eGFR decline, most predominantly in HF.
However, the most current CKD status (based on the
mean estimate during the same 2-year slope periods and
updated over time) was more consistently associated
with all CVD event types independently of disease
progression. Previous studies established an increasing
prevalence of CKD2,19 and its importance to CVD risk,
especially among subjects with both T2D and
CKD.14,26,27 To the authors' knowledge, this study is
the first to assess both progression of renal disease and
current renal status in relation to the development of1657
CLINICAL RESEARCH CS Cabrera et al.: Diabetic Nephropathymacrovascular outcomes, independantly of risk factors
such as hypertension and cardiovascular medication, to
better understand the underlying mechanisms of renal
disease in this contemporary cohort of persons with
T2DM.
Declining renal function over 10 years is a signifi-
cant risk for CVD at any point in time throughout the
trajectory of a T2DM patient’s disease history and
beyond current renal status. We found that over one-
fourth of subjects met our criteria for fast progressors
at baseline with a decreasing slope of >3 ml/min/1.73
m2 (slope category < –3). A recent publication27 in a
large contemporary population of US adults with 30–59
ml/min/1.73 m2 eGFR demonstrated that accelerated
progression of kidney dysfunction within 2 years
affected approximately 1 in 4 patients with diabetes
and 1 in 7 without it. They noted, as also illustrated in
this study, that the strongest independent correlates of
fast CKD progression included elevated systolic blood
pressure and HF.
When evaluating the statistical risk for current eGFR
status, we found that the most current status of eGFR
was more strongly associated with CVD risk across all
event types. Lower updated mean measures of eGFR <
30 mL/min/1.73 m2 estimated the greatest risk for
incident CVD compared with those with mean eGFR
estimates > 60 mL/min/1.73 m2. Overall, measures of
eGFR slope and mean appear to capture different as-
pects of the disease (rate of renal deterioration and
current status). When analyzed in the same model,
current eGFR status (updated mean eGFR) was more
strongly associated with CVD outcomes compared with
eGFR slope estimates. Among the fastest progressors,
only eGFR slope category < –3 indicated a significant
increase in risk for heart failure and the MACE plus
composite events.
When modeling renal data, the analytical value of
current status as estimated by the updated mean eGFR
and the rate of decline over time as captured by slope
estimates evaluate different effects on health outcomes.
Although it is a weaker risk factor in the statistical
models, the eGFR slope estimates added to the CVD risk
profile beyond the patient’s last recorded mean eGFR
value. This may affect clinical practice and clinical trial
decision processes. By better describing the nonline-
arity of renal disease progression and comparing this
with a patient’s most current renal status, a more ho-
listic picture may be obtained and more timely treat-
ment provided.
As mentioned, additional analyses were conducted
to assess the 2 main parameters (updated mean eGFR
and eGFR updated slope) in the same model. The strong
associations noted between both variables and CVD
events persisted, but the updated mean eGFR was an1658overall stronger statistical risk factor. In addition,
when assessed in a categorical manner, baseline slope
became a significant factor of MACE plus and HF,
indicating that the rate of decline possibly at any point
throughout a subject’s history provides important
clinical information. We also attempted to assess the
potential interaction between the eGFR updated slope
and updated mean eGFR to explore additional complex
patient segmentations. However, we could not test
statistical significance for this interaction owing to an
insufficient dataset size. The interaction between the
updated mean eGFR and age was tested to assess the
natural deteriorating impact of age on the cardiorenal
system, but we found it not to be significant in all
models.
In a recent global meta-analysis, the prevalence of
CKD in Europe was approximately 12% across stages
3–5 and a greater proportion were women.2 In the
study be Go et al.28 from 2018, as well as our study,
most T2DM subjects had advanced CKD, likely owing
to the difficulty of identifying subjects during the more
asymptomatic early stages of disease while in primary
health care. Another important distinction among older
T2DM subjects relates to hypertensive medication, for
which a substantial gap exists between guideline rec-
ommendations and real-world prescribing patterns for
RAASi among T2DM CKD patients with CVD comor-
bidities.29 The subjects in our study averaged age 64
years and the vast majority were receiving RAASi
medication (82%). This descriptive pattern may change
as the population becomes more severely diseased; less
than a quarter had T2DM over 5 years.29 This study
supports the growing body of evidence that CKD in-
creases CVD risk independently of hypertension and
T2DM26,30,31 and at any point in time throughout the
trajectory of a T2DM patient’s disease history of
declinining renal function. The strongest independent
risk factors for CVD outcomes in addition to eGFR
measures, both in our study and as previously
demonstrated, were age, male gender, smoking status,
hypertensive treatment, and duration of T2DM before
CKD diagnosis. More difficult to disentangle in this
study was the association between hyperkalemic status
at baseline and MACE plus in addition to the high CVD
risk noted among those receiving antihypertensive
treatment. The association between hypertensive
treatment and CVD outcomes may have been due to
confounding by indication, reflecting a more diseased
state, even during the baseline period. Therefore,
metrics to estimate CKD progression more precisely are
critical for the optimal timing of CVD interventions
such as antihypertensive (RAASi or mineralocorticoid
receptor antagonist) and antidiabetic medication such
as sodium-glucose cotransporter-2 inhibitors. In ourKidney International Reports (2020) 5, 1651–1660
CS Cabrera et al.: Diabetic Nephropathy CLINICAL RESEARCHstudy, the impact of RAASi medication may have
attenuated the association noted between renal disease
progression and future CVD events. Hence, future
retrospective and prospective studies are warranted in
which the renal metrics studied here (updated mean
eGFR and updated eGFR slope) are further analyzed in
conjunction with different pharmacological CVD in-
terventions to identify optimal time points for interven-
tion as well as therapeutic target levels. The risk for
cardiorenal outcomes may improve over time if renal
health is maintained, and especially so among T2DM
populations, as was recently demonstrated in a US study
that demonstrated reductions in CVD outcomes.28
Along with unmeasured confounding, there were
other relevant limitations to this study. Information on
laboratory methods of measuring creatinine levels,
which may influence eGFR levels to some extent, was
not always available.31 However, similar creatinine
levels were used to estimate both slope and updated
mean values. In addition, almost a quarter of the sub-
jects were missing low-density lipoprotein and/or tri-
glyceride values at baseline. However, the proportion
of subjects who experienced a CVD outcome was
similar between those with measures for low-density
lipoprotein and/or triglycerides (HF, 5.4%; MI, 1.4%;
IS, 0.9%; and MACE, 7.3%) compared with those with
missing values (HF, 6%; MI, 1.8%; IS, 1.2%; and
MACE, 8.5%). Therefore, we believe the results were
not skewed and the values were missing at random.
From a statistical perspective, power was insufficient to
assess interaction factors in the same model including
both the eGFR updated mean and the updated slope.
Finally, impaired kidney function and HF risk may
occur in the prediabetic stages, making it difficult to
assess risk factors in early asymptomatic stages of these
diseases. Despite the limitations highlighted here, this
remains a novel study assessing renal function decline
over a long follow-up. It allowed the inclusion of
multiple measures of eGFR, making it well-suited to
study CKD progression rates adequately in subjects
with T2DM and newly diagnosed CKD. Future studies
may further assess these measures of eGFR using more
complex marginal structural modeling techniques also
to study the changing risk factor profile of CKD
patients.
This study demonstrates that there is a strong associ-
ation between CKD, based on eGFR, and the risk for CVD
morbidity in a contemporary cohort of persons with
T2DM. We found that the rate of progression and the
cumulative status of CKD describe distinct aspects of the
cardiorenal risk in personswith T2DM.More specifically,
updated mean eGFR proved to be an important marker of
current renal function independently of the rate of dis-
ease progression. The rate of renal deterioration remainedKidney International Reports (2020) 5, 1651–1660highly correlated with incident HF events in T2DM
subjects independently of most current renal health. This
knowledge may be used in future clinical practice to
providemore timelymedical intervention to prevent CVD
in patients with CKD.
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TRANSLATIONAL STATEMENT
This study demonstrates a strong association between
chronic kidney disease and cardiovascular disease
morbidity in a cohort of persons with type 2 diabetes
mellitus. We found that the rate of progression and the
cumulative status of chronic kidney disease describe1659
CLINICAL RESEARCH CS Cabrera et al.: Diabetic Nephropathydistinct aspects of the cardiorenal risk in persons with type
2 diabetes mellitus. More specifically, updated mean
estimated glomerular filtration rate proved to be an
important marker of current renal function independently
of the rate of disease progression, whereas the rate of
renal deterioration remained highly correlated with the
incident hazard ratio. This knowledge may be used in
future clinical practice to provide more timely medical
intervention to prevent cardiovascular disease in patients
with chronic kidney disease.
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